Screener
Arcus Biosciences RCUS Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total non-operating income, net | 5 | 8 | 11 | 18 |
| Income (loss) before income taxes | (91) | — | (219) | (112) |
| Income tax expense | — | — | — | — |
| Net income (loss) | $(91) | — | $(219) | $(112) |
| Net income (loss) per share: | ||||
| Basic | $(0.72) | — | $(1.74) | $(1.09) |
| Diluted | $(0.72) | — | $(1.74) | $(1.09) |
| Shares used to compute net income (loss) per share: |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's business segments — net loss?
- Arcus Biosciences (RCUS) reported business segments — net loss of -$91M in Q2 2026.
- What is the long-term trend for Arcus Biosciences's business segments — net loss?
- Over 3 years (2022 to 2025), Arcus Biosciences's business segments — net loss has grown at a 9.8% compound annual growth rate (CAGR), from -$267M to -$353M.
- What does business segments — net loss mean?
- Measures the bottom-line financial performance of the segment after accounting for all revenues and operating expenses. For clinical-stage companies, this metric highlights the burn rate associated with advancing the product pipeline toward regulatory milestones.
Ask your AI about Arcus Biosciences's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude